RespireRx Pharmaceuticals Inc.
RSPI
$0.0021
$0.0011110.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.31% | 73.89% | -41.13% | -47.04% | -40.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.52% | 32.17% | -36.73% | -56.98% | -33.08% |
| Operating Income | 14.52% | -32.17% | 36.73% | 56.98% | 33.08% |
| Income Before Tax | 16.31% | -41.79% | 50.00% | 62.56% | 33.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.31% | -41.79% | 50.00% | 62.56% | 33.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.31% | -41.79% | 50.00% | 62.56% | 33.31% |
| EBIT | 14.52% | -32.17% | 36.73% | 56.98% | 33.08% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 89.13% | 47.44% | 64.77% | 31.58% | -15.00% |
| Normalized Basic EPS | 57.14% | 10.71% | 63.64% | 57.45% | 60.38% |
| EPS Diluted | 89.13% | 47.44% | 64.77% | 31.58% | -15.00% |
| Normalized Diluted EPS | 57.14% | 10.71% | 63.64% | 57.45% | 60.38% |
| Average Basic Shares Outstanding | 124.49% | 58.57% | 40.13% | 19.32% | 31.94% |
| Average Diluted Shares Outstanding | 124.49% | 58.57% | 40.13% | 19.32% | 31.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |